Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463068 · ClinicalTrials.gov registry record · Phase 3
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
A Phase 3 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 3
- Development phase
- 911
- Enrollment target
NCT05463068 is a Phase 3 study that has completed, run by Novavax. The registered enrollment target is 911 participants.
The verdict
NCT05463068, a Phase 3 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 911 participants
- Enrollment target
Study Summary
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
Interventions
- DRUG NVX-Cov2373
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05463068
The ClinicalTrials.gov registry entry for NCT05463068 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 911 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NVX-Cov2373 is the first listed.
NCT05463068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05463068 about?
NCT05463068 is a clinical study titled "Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults". This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
What is the current status of trial NCT05463068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 911 participants. The study started on 2022-07-11. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT05463068?
The interventions under investigation include: NVX-Cov2373 (DRUG).
Who is sponsoring clinical trial NCT05463068?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.